Arvinas Inc
NASDAQ:ARVN
Intrinsic Value
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. [ Read More ]
The intrinsic value of one ARVN stock under the Base Case scenario is 11.8 USD. Compared to the current market price of 32.54 USD, Arvinas Inc is Overvalued by 64%.
Valuation Backtest
Arvinas Inc
Run backtest to discover the historical profit from buying and selling ARVN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Arvinas Inc
Current Assets | 1.3B |
Cash & Short-Term Investments | 1.3B |
Receivables | 7.2m |
Other Current Assets | 12m |
Non-Current Assets | 24.4m |
PP&E | 14m |
Other Non-Current Assets | 10.4m |
Current Liabilities | 257.1m |
Accounts Payable | 110m |
Accrued Liabilities | 75.6m |
Other Current Liabilities | 71.5m |
Non-Current Liabilities | 387.5m |
Long-Term Debt | 800k |
Other Non-Current Liabilities | 386.7m |
Earnings Waterfall
Arvinas Inc
Revenue
|
78.5m
USD
|
Operating Expenses
|
-480m
USD
|
Operating Income
|
-401.5m
USD
|
Other Expenses
|
34.2m
USD
|
Net Income
|
-367.3m
USD
|
Free Cash Flow Analysis
Arvinas Inc
ARVN Profitability Score
Profitability Due Diligence
Arvinas Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
Arvinas Inc's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
ARVN Solvency Score
Solvency Due Diligence
Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Score
Arvinas Inc's solvency score is 63/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARVN Price Targets Summary
Arvinas Inc
According to Wall Street analysts, the average 1-year price target for ARVN is 72.25 USD with a low forecast of 49.49 USD and a high forecast of 115.5 USD.
Ownership
ARVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ARVN Price
Arvinas Inc
Average Annual Return | 30.87% |
Standard Deviation of Annual Returns | 75.37% |
Max Drawdown | -87% |
Market Capitalization | 2.2B USD |
Shares Outstanding | 68 083 904 |
Percentage of Shares Shorted | 14.09% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 280 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three lead product candidates are ARV-110, ARV-471 and ARV-766. The company develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). The company develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The company develops ARV-766, a PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate.
Contact
IPO
Employees
Officers
The intrinsic value of one ARVN stock under the Base Case scenario is 11.8 USD.
Compared to the current market price of 32.54 USD, Arvinas Inc is Overvalued by 64%.